Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
about
Asymmetric dimethyarginine as marker and mediator in ischemic strokeAsymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic reviewArginine/Asymmetric Dimethylarginine Ratio in Colorectal Surgery.Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance.Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine.Synthesis and evaluation of carbocyanine dyes as PRMT inhibitors and imaging agents.Identification of small-molecule enhancers of arginine methylation catalyzed by coactivator-associated arginine methyltransferase 1.Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized studyAsymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease.Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring CohortAsymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective StudiesAssociation of dimethylarginines and mediators of inflammation after acute ischemic strokeEffects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial.Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort.Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis.Asymmetric dimethylarginine, endothelial dysfunction and renal diseaseThe endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases.Renin-angiotensin system blockade promotes a cardio-renal protection in albuminuric homozygous sickle cell patients.
P2860
Q26864318-011F511F-9EB3-450C-A8D7-C0E348F01220Q33646665-01E2BB5C-6EEC-4BCA-A33E-957ABD5B7978Q33763284-5A858610-DA92-4C3A-9B45-1490B690ED0CQ33767571-2358860E-24EC-4388-9893-67B4E3C8AA7CQ33816492-C718D914-850D-40CF-973B-118E54CD3E70Q34323066-FB7A318A-A1EB-48EE-9CA4-C97A3DEF9255Q34456824-6818C06B-D324-4675-B254-FE592B026038Q34467988-5685E468-2937-4093-AE05-90C964628388Q35090446-A6B3F160-7A05-4870-A81D-67C0EE046FBCQ35572566-86D31026-9EB2-408C-9256-5D1AA324EFAFQ36182184-0746DE24-22E9-4073-BB19-EFFD91E21146Q36498512-B6D73DA9-D41A-485F-9CD1-3F1FAC5E64DBQ36845012-4CB57BC7-F9A8-4DBC-AEE4-6D4B83AE3640Q37359838-FC4DD867-B5BF-49AE-AE26-BCCAD073788CQ37704715-492FB0F8-C285-42D9-9C1E-0EB50144AC4FQ38056493-4B6EBCBF-9A05-4BBD-A5F5-CA0F87955E4AQ38203518-8E213113-9392-45E9-9DB0-A180E04B3685Q47763028-526C5F03-B428-40DF-AC30-41C5543CEA1D
P2860
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
@ast
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
@en
type
label
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
@ast
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
@en
prefLabel
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
@ast
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
@en
P2860
P1433
P1476
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
@en
P2093
Renke Maas
P2860
P304
P356
10.1191/1358863X05VM605OA
P478
10 Suppl 1
P577
2005-07-01T00:00:00Z